Tradestie Institutional Equity Comparison Engine

TBPH vs XOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-09-23 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TBPH Overall Edge

TBPH Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Options & Structure while XOMA counters with relative strength in Momentum & Technical. Fundamentally, TBPH trades at 13.4x Forward P/E with 8.9% operating margin (-20.9% YoY revenue) versus XOMA at 21.5x Forward P/E and -3.9% operating margin (-22.6% YoY). In options structure, TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro) against XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TBPH
TBPH 13.4x vs XOMA 21.5x Fwd P/E
Growth & Margin Winner TBPH
Op Margin 8.9% vs -3.9% ยท YoY -20.9% vs -22.6%
Momentum & Technical Winner XOMA
1Y +21.0% vs +44.0% ยท 52W Pos 50% vs 78%
Options & Structure Winner TBPH
UNCLASSIFIED (16th %ile IV) vs UNCLASSIFIED (100th %ile IV)
TBPH NASDAQ
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
1M Return +0.12%
1Y Return +21.04%
Forward P/E 13.4x
Unified AI Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TBPH +21.04% XOMA +43.98% Spread: +12.01 pp (TBPH Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TBPH TTM Op. Margin: 8.9% XOMA TTM Op. Margin: -3.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs XOMA. Trailing 12-month operating profitability (TBPH 8.9% vs XOMA -3.9%) and valuation multiples (TBPH 13.4x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TBPH (6) vs XOMA (4)
Institutional Metric TBPH XOMA Criterion Row Winner
Market Capitalization Scale $884.2M $781.8M Larger Scale TBPH
Trailing P/E Ratio Valuation 16.4x 28.2x Lower Multiple TBPH
Forward P/E Ratio Valuation 13.4x 21.5x Lower Multiple TBPH
Revenue Growth (YoY) Growth -20.9% -22.6% Higher Growth TBPH
Operating Margin (TTM) Profitability 8.9% -3.9% Higher Margin TBPH
Net Profit Margin Profitability 51.6% 69.6% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency 20.9% 34.2% Higher ROE XOMA
52-Week Range Position Momentum 50% ($13โ€“$21) 78% ($22โ€“$45) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 0.48ฮฒ ยท 2% Vol 0.68ฮฒ ยท 37% Vol Lower Realized Risk TBPH
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TBPH vs XOMA Buy Guide
TBPH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live TBPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TBPH nor XOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.